Two large 72-week clinical trials that evaluated terzepatide in individuals who were overweight or obese found that by the end of the study, people who also dieted and exercised reported statistically significant weight loss compared to those who took the placebo
Retrieved March 10, 2026, from 16 For the majority of the period depicted in Figure 2, chronic weight management was the sole approved indication for Wegovy, Zepbound, and Saxenda
Headaches: Reported at rates slightly above placebo, headaches can often be attributed to dehydration or rapid dietary changes rather than direct pharmacological effects
That option wont be available to athletes
Longato E, Di Camillo B, Sparacino G, Tramontan L, Avogaro A, Fadini GP
Keeping a simple injection diary or using a body diagram can help track rotation